Tonix Pharmaceuticals Secures GPO Agreement Covering 35 Million Lives for TONMYA Fibromyalgia Treatment
Tonix Pharmaceuticals announced a group purchasing organization agreement effective May 1, 2026, covering approximately 35 million U.S. commercial lives for its FDA-approved non-opioid fibromyalgia treatment TONMYA, expanding patient access.
